TLDR Injective launches onchain Pre-IPO market, reshaping private equity access. OpenAI debuts onchain Pre-IPO futures via Injective’s decentralized platform. SpaceX, Anthropic, and more join Injective’s new Pre-IPO trading revolution. $13T Pre-IPO market goes onchain with Injective’s perpetual equity contracts. Injective opens global Pre-IPO access with OpenAI and upcoming tech giants. Injective has launched the first [...] The post Injective Brings the Pre-IPO Market Onchain for the First Time appeared first on CoinCentral.TLDR Injective launches onchain Pre-IPO market, reshaping private equity access. OpenAI debuts onchain Pre-IPO futures via Injective’s decentralized platform. SpaceX, Anthropic, and more join Injective’s new Pre-IPO trading revolution. $13T Pre-IPO market goes onchain with Injective’s perpetual equity contracts. Injective opens global Pre-IPO access with OpenAI and upcoming tech giants. Injective has launched the first [...] The post Injective Brings the Pre-IPO Market Onchain for the First Time appeared first on CoinCentral.

Injective Brings the Pre-IPO Market Onchain for the First Time

3 min read

TLDR

  • Injective launches onchain Pre-IPO market, reshaping private equity access.
  • OpenAI debuts onchain Pre-IPO futures via Injective’s decentralized platform.
  • SpaceX, Anthropic, and more join Injective’s new Pre-IPO trading revolution.
  • $13T Pre-IPO market goes onchain with Injective’s perpetual equity contracts.
  • Injective opens global Pre-IPO access with OpenAI and upcoming tech giants.

Injective has launched the first onchain Pre-IPO market, enabling users to trade top private companies directly through its blockchain. This development marks a significant shift in decentralized finance, providing access to the previously exclusive $13 trillion pre-IPO market. With this launch, Injective is reshaping how global markets access private equity assets.

OpenAI Leads New Onchain Pre-IPO Listings

Injective has introduced perpetual futures for OpenAI, allowing users to gain exposure to the firm’s private valuation. These Pre-IPO contracts can be traded with leverage, giving participants advanced tools in a fully onchain environment. Unlike traditional models, Injective’s solution ensures programmability and capital efficiency.

The platform delivers real-time data from SEDA and Caplight Data to support accurate pricing of Pre-IPO assets. Users can now access OpenAI through Helix Markets and other major Injective apps. The model stands apart by being composable and offering perpetual access without expiration.

Pre-IPO market activity has typically been inaccessible to the broader ecosystem.  With Injective’s Layer 1 infrastructure, retail traders can now interact with equity-based derivatives in real-time. This expansion enhances transparency while reducing barriers in high-growth segments, such as AI and data.

SpaceX, Anthropic and Perplexity to Follow

Following OpenAI, Injective plans to add companies such as SpaceX, Anthropic, and Perplexity to its Pre-IPO market lineup. These firms belong to fast-expanding sectors where demand for early-stage exposure has surged. Pre-IPO contracts offer a new entry point for those interested in high-value private firms.

Each Pre-IPO perpetual contract reflects the valuation of the underlying company, updated continuously via onchain oracle feeds. As the market matures, Injective expects broader listings and deeper liquidity across key verticals. This move also reflects Injective’s long-term plan to mirror traditional finance in a decentralized framework.

Earlier this year, Injective partnered with Republic to explore blockchain-based equity instruments. These developments support the transition of private equity markets to onchain formats. The current rollout builds on that foundation, expanding access and optionality for traders worldwide.

New Era for Global Pre-IPO Market Access

Injective has processed $1 billion in real-world asset perpetual futures trading over 30 days. This signals a growing appetite for onchain exposure to real-world financial instruments, especially in the pre-IPO market. The surge indicates confidence in the blockchain’s ability to handle complex financial products.

By making Pre-IPO markets onchain, Injective offers a seamless trading experience that relies on no intermediaries. This simplifies user access to private markets, which are typically limited to accredited participants. With efficient collateral management and full transparency, Injective enhances accessibility.

As October progresses, Injective will expand its Pre-IPO listings to include firms such as Notion, xAI, Revolut, Airtable, and Monzo. These companies represent leading names in technology and finance, further legitimizing the onchain evolution of the Pre-IPO market. The project continues to advance its goal of decentralizing every aspect of global finance.

 

The post Injective Brings the Pre-IPO Market Onchain for the First Time appeared first on CoinCentral.

Market Opportunity
Octavia Logo
Octavia Price(VIA)
$0,00126
$0,00126$0,00126
-%10,70
USD
Octavia (VIA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
XRP Ledger Unlocks Permissioned Domains With 91% Validator Backing

XRP Ledger Unlocks Permissioned Domains With 91% Validator Backing

XRP Ledger activated XLS-80 after 91% validator approval, enabling permissioned domains for credential-gated use on the public XRPL. The XRP Ledger has activated
Share
LiveBitcoinNews2026/02/06 13:00
XRPL Adds Institutional Lending and Privacy Tools in Ripple’s 2026 Roadmap

XRPL Adds Institutional Lending and Privacy Tools in Ripple’s 2026 Roadmap

Ripple shared a new Institutional DeFi roadmap showing how the XRP Ledger is being shaped for everyday use by banks, asset managers, and regulated financial firms
Share
Tronweekly2026/02/06 13:00